We are delighted to have advised Haleon on their international carve-out
Haleon UK Trading Limited (“Haleon”) is a subsidiary of Haleon PLC which was formed in July 2019 after a spin off from GSK and Pfizer.
As part of Haleon’s strategy to proactively manage its portfolio, it determined Lamisil, a fungal infection treatment, was a non-core brand and signed an agreement to divest the brand to Karo Healthcare in July 2023. Lamisil is a market-leading, global OTC brand sold in over 100 markets; with 66 markets in scope of the sale. A complex market cut over was planned in 14 phases, over 28 months.
We combined our strong sector credentials with our deep carve-out experience to actively manage a complex separation process that required extensive international market input. This provided confidence to both Haleon and the buyer key stakeholders that the process was on track, and all risks were being actively managed and mitigated in advance of Day 1.
Any issues or risks that could have potentially impacted the transaction timetable were actively managed by defining viable solutions and ensuring alignment with the buyer at every stage.
Deal Signing occurred without disruption, in-line with the transaction goals, and a phased and controlled Completion is no underway.
